Effect of Levosimendan on Respiratory Muscle Function in Healthy Subjects

Pilot Study on the Effects of Levosimendan on in Vivo Respiratory Muscle Function in Healthy Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01101620

Acronym

LSD1

Enrollment

Registered

2010-04-12

Start date

2010-04-30

Completion date

2010-09-30

Last updated

2011-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Muscle Function

Brief summary

The purpose of this study is to investigate if levosimendan improves contractile performance of the diaphragm in healthy subjects.

Interventions

DRUGLevosimendan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* informed consent

Exclusion criteria

* use of any prescript medication * chronic hiccups * pre-existent muscle disease (congenital or acquired) or diseases / disorders know to be associated with myopathy including diabetes and auto-immune diseases. * pre-existent lung disease * pre-existent cardiac disease (based on history, electrocardiography and transthoracic echocardiography) * pregnancy, breast feeding * upper airway / esophageal pathology * phrenic nerve lesions * any metals in body (pacemaker, splinters, metal stiches)

Design outcomes

Primary

Measure	Time frame
Contractility of the diaphragm elicited with magnetic stimulation of the phrenic nerves	Multiple measurements within 4 hours after administration of study medication
Fatiguability of the diaphragm	Multiple measurements within 4 hours after administration of study medication

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026